$SNWV
SANUWAVE Health, Inc.

2024 Q1 Form 10-K Financial Statement

#000114036124014611 Filed on March 21, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $5.786M $6.994M $20.40M
YoY Change 53.27% 27.16% 21.84%
Cost Of Revenue $1.584M $2.159M $6.035M
YoY Change 25.52% 24.01% 39.34%
Gross Profit $4.202M $4.835M $14.36M
YoY Change 67.21% 28.62% 15.73%
Gross Profit Margin 72.62% 69.13% 70.41%
Selling, General & Admin $4.907M $3.464M $13.57M
YoY Change 17.65% -46.8% -32.24%
% of Gross Profit 116.78% 71.64% 94.49%
Research & Development $163.0K $143.0K $579.0K
YoY Change 24.43% 95.89% 2.12%
% of Gross Profit 3.88% 2.96% 4.03%
Depreciation & Amortization $218.0K $248.0K $1.028M
YoY Change -15.83% 29.84% 7.98%
% of Gross Profit 5.19% 5.13% 7.16%
Operating Expenses $5.252M $3.796M $14.90M
YoY Change 16.95% -43.97% -30.24%
Operating Profit -$1.050M $1.039M -$540.0K
YoY Change -46.92% -134.45% -93.97%
Interest Expense -$6.061M $17.20M -$25.24M
YoY Change -45.27% -497.39% -1104.54%
% of Operating Profit 1655.73%
Other Income/Expense, Net -$3.478M -$3.000K -$25.26M
YoY Change -68.67% 1786.71%
Pretax Income -$4.528M $18.24M -$25.78M
YoY Change -65.38% -323.63% 150.83%
Income Tax $4.000K $4.000K
% Of Pretax Income 0.02%
Net Earnings -$4.528M $18.24M -$25.81M
YoY Change -65.38% -323.52% 150.72%
Net Earnings / Revenue -78.26% 260.72% -126.52%
Basic Earnings Per Share $0.00 -$0.03
Diluted Earnings Per Share $0.00 $0.02 -$0.03
COMMON SHARES
Basic Shares Outstanding 1.141B 1.026B 793.9M
Diluted Shares Outstanding 1.162B 793.9M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.936M $1.797M $1.797M
YoY Change 2669.81% 55.85% 55.85%
Cash & Equivalents $2.936M $1.797M
Short-Term Investments
Other Short-Term Assets $2.426M $1.722M $1.722M
YoY Change 553.91% 202.11% 202.11%
Inventory $2.461M $2.951M $2.951M
Prepaid Expenses
Receivables $3.008M $3.314M $3.314M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $10.83M $9.784M $9.784M
YoY Change 139.78% 47.79% 47.79%
LONG-TERM ASSETS
Property, Plant & Equipment $975.0K $938.0K $938.0K
YoY Change 28.63% 25.07% 25.07%
Goodwill $7.260M $7.260M
YoY Change 0.0% 0.0%
Intangibles $4.258M $4.434M
YoY Change -14.19% -13.69%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $12.49M $12.63M $12.63M
YoY Change -3.75% -4.69% -4.69%
TOTAL ASSETS
Total Short-Term Assets $10.83M $9.784M $9.784M
Total Long-Term Assets $12.49M $12.63M $12.63M
Total Assets $23.32M $22.42M $22.42M
YoY Change 33.3% 12.8% 12.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.062M $5.705M $5.705M
YoY Change -3.84% 29.66% 29.66%
Accrued Expenses $6.849M $5.999M $12.11M
YoY Change -19.89% -29.52% -9.29%
Deferred Revenue $107.0K $92.00K
YoY Change 72.58% 53.33%
Short-Term Debt $18.91M $22.85M $22.85M
YoY Change 26.1% 58.53% 58.53%
Long-Term Debt Due $10.00M $7.109M $7.109M
YoY Change -59.28% -70.53% -70.53%
Total Short-Term Liabilities $70.18M $64.76M $64.75M
YoY Change -0.66% 7.59% 7.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $735.0K $839.0K $839.0K
YoY Change 20.69% 25.6% 25.6%
Total Long-Term Liabilities $735.0K $839.0K $839.0K
YoY Change 15.38% 20.55% 25.6%
TOTAL LIABILITIES
Total Short-Term Liabilities $70.18M $64.76M $64.75M
Total Long-Term Liabilities $735.0K $839.0K $839.0K
Total Liabilities $70.92M $65.59M $65.59M
YoY Change -0.52% 7.74% 7.74%
SHAREHOLDERS EQUITY
Retained Earnings -$224.6M -$220.0M
YoY Change 8.32% 13.29%
Common Stock $1.140M $1.140M
YoY Change 105.04% 107.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$47.60M -$43.18M -$43.18M
YoY Change
Total Liabilities & Shareholders Equity $23.32M $22.42M $22.42M
YoY Change 33.3% 12.8% 12.8%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$4.528M $18.24M -$25.81M
YoY Change -65.38% -323.52% 150.72%
Depreciation, Depletion And Amortization $218.0K $248.0K $1.028M
YoY Change -15.83% 29.84% 7.98%
Cash From Operating Activities $1.100M -$1.285M -$4.538M
YoY Change -396.5% -67.82% -73.57%
INVESTING ACTIVITIES
Capital Expenditures $114.0K
YoY Change 533.33%
Acquisitions
YoY Change
Other Investing Activities $8.000K $21.00K
YoY Change -101.16% -93.67%
Cash From Investing Activities -$114.0K $177.0K $21.00K
YoY Change 533.33% -125.65% -93.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 42.00K 1.855M 5.211M
YoY Change -106.42% -60.7% -70.02%
NET CHANGE
Cash From Operating Activities 1.100M -1.285M -4.538M
Cash From Investing Activities -114.0K 177.0K 21.00K
Cash From Financing Activities 42.00K 1.855M 5.211M
Net Change In Cash 1.139M 747.0K 644.0K
YoY Change -208.79% 1918.92% 20.6%
FREE CASH FLOW
Cash From Operating Activities $1.100M -$1.285M -$4.538M
Capital Expenditures $114.0K
Free Cash Flow $986.0K
YoY Change -353.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1153000
CY2023Q4 us-gaap Goodwill
Goodwill
7260000
CY2023Q4 us-gaap Assets
Assets
22416000
CY2023Q4 snwv Accrued Interest Payable Related Parties Current
AccruedInterestPayableRelatedPartiesCurrent
669000
CY2022Q4 snwv Accrued Interest Payable Related Parties Current
AccruedInterestPayableRelatedPartiesCurrent
788000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
92000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
947000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2500000000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
548737651
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
548737651
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1140000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
549000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
175842000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
152750000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-220049000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-194242000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-111000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-67000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-43178000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-41010000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22416000
CY2023 us-gaap Gross Profit
GrossProfit
14363000
CY2022 us-gaap Gross Profit
GrossProfit
12411000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8674000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12556000
CY2023 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4898000
CY2022 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7474000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
579000
CY2022 us-gaap Operating Expenses
OperatingExpenses
21363000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-540000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-8952000
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-418000
CY2022 snwv Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
-16654000
CY2023 snwv Loss On Issuance Of Debt
LossOnIssuanceOfDebt
0
CY2022 snwv Loss On Issuance Of Debt
LossOnIssuanceOfDebt
3434000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-25807000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-10293000
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-44000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
6000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25851000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10287000
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
793850994
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
793850994
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
549470787
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-10293000
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-418000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2022 snwv Loss On Issuance Of Debt
LossOnIssuanceOfDebt
3434000
CY2023 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
6911000
CY2022 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
4950000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
332000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4538000
CY2023 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
3026000
CY2022 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
16227000
CY2023 us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
0
CY2022 us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
2940000
CY2023 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
100000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5211000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17384000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
644000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
534000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1153000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
619000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1797000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1153000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
1958000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
3712000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1237000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1037000
CY2022Q4 us-gaap Goodwill
Goodwill
7260000
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
12632000
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
13253000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
4052000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
319000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
64755000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
60215000
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
839000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
668000
CY2023Q4 us-gaap Liabilities
Liabilities
65594000
CY2022Q4 us-gaap Liabilities
Liabilities
60883000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19873000
CY2023 us-gaap Revenues
Revenues
20398000
CY2022 us-gaap Revenues
Revenues
16742000
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
4331000
CY2023 snwv Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
9621000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-25263000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
549470787
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-38958000
CY2022 snwv Stock Issued During Period Value Cashless Warrant Exercises
StockIssuedDuringPeriodValueCashlessWarrantExercises
2166000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-10293000
CY2022 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
6000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-41010000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-25807000
CY2023 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-44000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-43178000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-25807000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1028000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
952000
CY2023 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
781000
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
253000
CY2023 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
224000
CY2022 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
888000
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
53000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1748000
CY2023 snwv Increase Decrease In Inventories Prepaid Expenses And Other Assets
IncreaseDecreaseInInventoriesPrepaidExpensesAndOtherAssets
3006000
CY2022 snwv Increase Decrease In Inventories Prepaid Expenses And Other Assets
IncreaseDecreaseInInventoriesPrepaidExpensesAndOtherAssets
72000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17169000
CY2023 us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
-21000
CY2022 us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
-332000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
21000
CY2023 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0
CY2022 us-gaap Repayments Of Debt
RepaymentsOfDebt
2981000
CY2023 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
170000
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
237000
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-50000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-13000
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001417663
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Auditor Firm
AuditorFirmId
688
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
000-52985
CY2023 dei Entity Registrant Name
EntityRegistrantName
SANUWAVE Health, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-1176000
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
11495 Valley View Road
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Eden Prairie
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55344
CY2023 dei City Area Code
CityAreaCode
952
CY2023 dei Local Phone Number
LocalPhoneNumber
656-1029
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
7700000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1140559527
CY2023 dei Auditor Name
AuditorName
Marcum LLP
CY2023 dei Auditor Location
AuditorLocation
New York, NY
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1797000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3314000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4029000
CY2023Q4 us-gaap Inventory Net
InventoryNet
2951000
CY2022Q4 us-gaap Inventory Net
InventoryNet
868000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1722000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
570000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
9784000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
6620000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
938000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
856000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4434000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5137000
CY2022Q4 us-gaap Assets
Assets
19873000
CY2023Q4 us-gaap Senior Notes Current
SeniorNotesCurrent
18278000
CY2022Q4 us-gaap Senior Notes Current
SeniorNotesCurrent
14416000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5705000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4400000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5999000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8512000
CY2023Q4 snwv Factoring Liabilities Current
FactoringLiabilitiesCurrent
1490000
CY2022Q4 snwv Factoring Liabilities Current
FactoringLiabilitiesCurrent
2130000
CY2023Q4 snwv Warrant Liability Current
WarrantLiabilityCurrent
14447000
CY2022Q4 snwv Warrant Liability Current
WarrantLiabilityCurrent
1416000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
5444000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
60000
CY2023Q4 snwv Operating Lease And Finance Lease Liability Noncurrent
OperatingLeaseAndFinanceLeaseLiabilityNoncurrent
492000
CY2022Q4 snwv Operating Lease And Finance Lease Liability Noncurrent
OperatingLeaseAndFinanceLeaseLiabilityNoncurrent
438000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
347000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
230000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2500000000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1140559527
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1140559527
CY2023 us-gaap Cost Of Revenue
CostOfRevenue
6035000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
567000
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
752000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
766000
CY2023 us-gaap Operating Expenses
OperatingExpenses
14903000
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
19000
CY2022 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
9000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1339000
CY2023 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-25803000
CY2022 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-10291000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2022 snwv Stock Issued During Period Warrants Exercised Value
StockIssuedDuringPeriodWarrantsExercisedValue
100000
CY2022 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3720000
CY2022 snwv Shares Issued For Settlement Of Debt And Warrants
SharesIssuedForSettlementOfDebtAndWarrants
1361000
CY2022 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
888000
CY2023 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
527000
CY2023 snwv Shares Issued For Settlement Of August2022 Debt
SharesIssuedForSettlementOfAugust2022Debt
18577000
CY2023 snwv Shares Issued For Settlement Of November2022 Debt
SharesIssuedForSettlementOfNovember2022Debt
4579000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
9621000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-16654000
CY2023 snwv Loss On Issuance Of Debt
LossOnIssuanceOfDebt
0
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1546000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2550000
CY2023 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
6306000
CY2022 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
3182000
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2093000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
69000
CY2023 us-gaap Proceeds From Secured Notes Payable
ProceedsFromSecuredNotesPayable
2994000
CY2022 us-gaap Proceeds From Secured Notes Payable
ProceedsFromSecuredNotesPayable
0
CY2023 snwv Payments Proceeds From Factoring
PaymentsProceedsFromFactoring
-639000
CY2022 snwv Payments Proceeds From Factoring
PaymentsProceedsFromFactoring
695000
CY2022 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
640000
CY2023 us-gaap Repayments Of Debt
RepaymentsOfDebt
0
CY2023 snwv Warrants Issued In Conjunction With Senior Secured And Convertible Promissory Note Payable
WarrantsIssuedInConjunctionWithSeniorSecuredAndConvertiblePromissoryNotePayable
1682000
CY2022 snwv Warrants Issued In Conjunction With Senior Secured And Convertible Promissory Note Payable
WarrantsIssuedInConjunctionWithSeniorSecuredAndConvertiblePromissoryNotePayable
4177000
CY2023 snwv Conversion Of Convertible Notes Payable And Accrued Interest To Common Stock
ConversionOfConvertibleNotesPayableAndAccruedInterestToCommonStock
23156000
CY2022 snwv Conversion Of Convertible Notes Payable And Accrued Interest To Common Stock
ConversionOfConvertibleNotesPayableAndAccruedInterestToCommonStock
0
CY2023 snwv Embedded Conversion Option With Issuances Of Convertible Debt
EmbeddedConversionOptionWithIssuancesOfConvertibleDebt
835000
CY2022 snwv Embedded Conversion Option With Issuances Of Convertible Debt
EmbeddedConversionOptionWithIssuancesOfConvertibleDebt
2760000
CY2023 snwv Common Shares Issued For Advisory Shares
CommonSharesIssuedForAdvisoryShares
302000
CY2022 snwv Common Shares Issued For Advisory Shares
CommonSharesIssuedForAdvisoryShares
0
CY2023 snwv Settlement Of Debt And Warrants With Stock
SettlementOfDebtAndWarrantsWithStock
0
CY2022 snwv Settlement Of Debt And Warrants With Stock
SettlementOfDebtAndWarrantsWithStock
1361000
CY2023 snwv Common Shares Issued In Conjunction With Senior Secured Debt
CommonSharesIssuedInConjunctionWithSeniorSecuredDebt
0
CY2022 snwv Common Shares Issued In Conjunction With Senior Secured Debt
CommonSharesIssuedInConjunctionWithSeniorSecuredDebt
3720000
CY2023 snwv Warrant Issuance In Conjunction With Convertible Notes
WarrantIssuanceInConjunctionWithConvertibleNotes
0
CY2022 snwv Warrant Issuance In Conjunction With Convertible Notes
WarrantIssuanceInConjunctionWithConvertibleNotes
1708000
CY2023 snwv Reclassification Of Warrant Liability Due To Cashless Warrant Exercise
ReclassificationOfWarrantLiabilityDueToCashlessWarrantExercise
0
CY2022 snwv Reclassification Of Warrant Liability Due To Cashless Warrant Exercise
ReclassificationOfWarrantLiabilityDueToCashlessWarrantExercise
2166000
CY2023 snwv Working Capital Balances Refinanced Into Convertible Notes Payable
WorkingCapitalBalancesRefinancedIntoConvertibleNotesPayable
0
CY2022 snwv Working Capital Balances Refinanced Into Convertible Notes Payable
WorkingCapitalBalancesRefinancedIntoConvertibleNotesPayable
2363000
CY2023 us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 36pt;"> <div style="font-weight: bold;"><span style="font-weight: bold;">1.</span></div> </td> <td style="align: left; vertical-align: top; width: auto;"> <div style="font-weight: bold;"> <div style="color: rgb(0, 0, 0); font-weight: bold;">Nature of the Business and Basis of Presentation</div> </div> </td> </tr> </table> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><br/> SANUWAVE Health, Inc. and Subsidiaries (“SANUWAVE” or the “Company”) is focused on the commercialization of its patented noninvasive and biological response activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.<br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: bold; font-style: italic;">Basis of Presentation - </span>The accompanying consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and with the instructions to for 10-K and Regulation S-X. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The functional currencies of the Company’s foreign operations are their local currencies. The financial statements of the Company’s foreign subsidiary have been translated into United States dollars. All balance sheet accounts have been translated using the exchange rates in effect at the balance sheet date. Income statement amounts have been translated using the average exchange rate for the year. Translation adjustments are reported in other comprehensive loss in the consolidated statements of comprehensive loss and as cumulative translation adjustments in accumulated other comprehensive loss in the consolidated balance sheets.</div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"><span style="font-weight: bold; font-style: italic;">Segment information <span style="font-weight: bold; font-style: normal;">-</span><span style="font-style: normal;"> </span></span>We have determined that we have one operating segment. Our revenues are primarily generated from sales in the United States. All significant expenses are generated, and all significant assets are located in the United States. </div> <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: bold; font-style: italic;">Reclassification</span> <span style="font-weight: bold; font-style: italic;"><span style="font-weight: bold; font-style: normal;">-</span> </span>Certain accounts in the prior period consolidated financial statements have been reclassified to conform to the presentation of the current year consolidated financial statements. These reclassifications had no effect on the previously reported operating results.</div>
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: bold; font-style: italic;">Estimates</span> – These consolidated financial statements have been prepared in accordance with U.S. GAAP. Because a precise determination of assets and liabilities, and correspondingly revenues and expenses, depend on future events, the preparation of consolidated financial statements for any period necessarily involves the use of estimates and assumptions. Actual amounts may differ from these estimates. These consolidated financial statements have, in management’s opinion, been properly prepared within reasonable limits of materiality and within the framework of the accounting policies summarized herein.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Significant estimates include the recording of allowances for credit losses, the net realizable value of inventory, fair value of goodwill and intangible assets, the determination of the valuation allowances for deferred taxes, litigation contingencies, estimated fair value of stock-based compensation, and the estimated fair value of embedded financial instruments, including warrants and embedded conversion options.</div>
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023 snwv Initial Warranty Period Of Device Product
InitialWarrantyPeriodOfDeviceProduct
P1Y
CY2023 us-gaap Costs And Expenses
CostsAndExpenses
484000
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
324000
CY2023 snwv Class Of Warrant Or Right Exercise Price
ClassOfWarrantOrRightExercisePrice
0.01
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
793851000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
549471000
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1377942000
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1811193000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
416000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
570000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2882000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
641000
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
347000
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
343000
CY2023Q4 us-gaap Inventory Net
InventoryNet
2951000
CY2022Q4 us-gaap Inventory Net
InventoryNet
868000
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
6825000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2391000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
6825000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1688000
CY2023Q4 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P3Y9M18D
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
704000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
704000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
704000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
704000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
704000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
487000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
158000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
1677000
CY2023Q4 snwv Accrued Registration Penalties Current
AccruedRegistrationPenaltiesCurrent
1583000
CY2022Q4 snwv Accrued Registration Penalties Current
AccruedRegistrationPenaltiesCurrent
1583000
CY2023Q4 snwv Accrued License Fees Current
AccruedLicenseFeesCurrent
892000
CY2022Q4 snwv Accrued License Fees Current
AccruedLicenseFeesCurrent
892000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
942000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
415000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2298000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4585000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
284000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1037000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5999000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8512000
CY2023Q4 snwv Accounts Receivable Transferred
AccountsReceivableTransferred
-1794000
CY2022Q4 snwv Accounts Receivable Transferred
AccountsReceivableTransferred
-2564000
CY2023Q4 snwv Accounts Receivable Reserve Amount
AccountsReceivableReserveAmount
304000
CY2022Q4 snwv Accounts Receivable Reserve Amount
AccountsReceivableReserveAmount
434000
CY2023Q4 snwv Factoring Liabilities Current
FactoringLiabilitiesCurrent
1490000
CY2022Q4 snwv Factoring Liabilities Current
FactoringLiabilitiesCurrent
2130000
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
8462000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1353000
CY2023Q4 snwv Debt Instrument Conversion Option
DebtInstrumentConversionOption
0
CY2023Q4 snwv Convertible Promissory Notes And Convertible Promissory Note Related Parties Current
ConvertiblePromissoryNotesAndConvertiblePromissoryNoteRelatedPartiesCurrent
7109000
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
25548000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
3766000
CY2022Q4 snwv Debt Instrument Conversion Option
DebtInstrumentConversionOption
2340000
CY2022Q4 snwv Convertible Promissory Notes And Convertible Promissory Note Related Parties Current
ConvertiblePromissoryNotesAndConvertiblePromissoryNoteRelatedPartiesCurrent
24122000
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2023 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-60000
CY2022 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-253000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
290000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
341000
CY2023 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-60000
CY2022 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-253000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
439000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
290000
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
204883000
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.2
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P2Y6M14D
CY2022 snwv Class Of Warrant Or Right Issuances In Period
ClassOfWarrantOrRightIssuancesInPeriod
1031276000
CY2022 snwv Class Of Warrant Or Right Weighted Average Exercise Price Of Issuances
ClassOfWarrantOrRightWeightedAverageExercisePriceOfIssuances
0.06
CY2022 snwv Class Of Warrant Or Right Exercised In Period
ClassOfWarrantOrRightExercisedInPeriod
27943000
CY2022 snwv Class Of Warrant Or Right Weighted Average Exercise Price Of Exercised
ClassOfWarrantOrRightWeightedAverageExercisePriceOfExercised
0.09
CY2022 snwv Class Of Warrant Or Right Forfeited Or Expired In Period
ClassOfWarrantOrRightForfeitedOrExpiredInPeriod
0
CY2022 snwv Class Of Warrant Or Right Weighted Average Exercise Price Of Forfeited Or Expired
ClassOfWarrantOrRightWeightedAverageExercisePriceOfForfeitedOrExpired
0
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1208216000
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.07
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P3Y6M18D
CY2023 snwv Class Of Warrant Or Right Issuances In Period
ClassOfWarrantOrRightIssuancesInPeriod
154451000
CY2023 snwv Class Of Warrant Or Right Weighted Average Exercise Price Of Issuances
ClassOfWarrantOrRightWeightedAverageExercisePriceOfIssuances
0.06
CY2023 snwv Class Of Warrant Or Right Exercised In Period
ClassOfWarrantOrRightExercisedInPeriod
0
CY2023 snwv Class Of Warrant Or Right Weighted Average Exercise Price Of Exercised
ClassOfWarrantOrRightWeightedAverageExercisePriceOfExercised
0
CY2023 snwv Class Of Warrant Or Right Forfeited Or Expired In Period
ClassOfWarrantOrRightForfeitedOrExpiredInPeriod
141095000
CY2023 snwv Class Of Warrant Or Right Weighted Average Exercise Price Of Forfeited Or Expired
ClassOfWarrantOrRightWeightedAverageExercisePriceOfForfeitedOrExpired
0
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1221572000
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.06
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y3D
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2500000000
CY2022 snwv Effective Income Tax Rate Reconciliation Nondeductible Expense Warrants Amount
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantsAmount
-3270000
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4026000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4905000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19255000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15511000
CY2023 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
1143000
CY2022 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
1231000
CY2023 us-gaap Revenues
Revenues
20398000
CY2022 us-gaap Revenues
Revenues
16742000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-25783000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-10279000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-20000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-12000
CY2023 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-25803000
CY2022 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-10291000
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
4000
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2000
CY2023 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
4000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2000
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-3564000
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-5657000
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-459000
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
753000
CY2023 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-3000
CY2022 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-1000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-4026000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-4905000
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2022Q4 us-gaap Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
0
CY2023Q4 us-gaap Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5485000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2161000
CY2023 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-307000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-473000
CY2023 snwv Effective Income Tax Rate Reconciliation Nondeductible Expense Warrants Amount
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseWarrantsAmount
2102000
CY2023 snwv Income Tax Reconciliation Registration Penalties
IncomeTaxReconciliationRegistrationPenalties
0
CY2022 snwv Income Tax Reconciliation Registration Penalties
IncomeTaxReconciliationRegistrationPenalties
67000
CY2023 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-332000
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
934000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
42484000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
38323000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
27000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
24000
CY2023Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
70000
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
9000
CY2023Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
1162000
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
1325000
CY2023Q4 snwv Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
192000
CY2022Q4 snwv Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
150000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1495000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1487000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
338000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
750000
CY2023Q4 snwv Deferred Tax Assets Tax Deferred Expense Equity Cost
DeferredTaxAssetsTaxDeferredExpenseEquityCost
235000
CY2022Q4 snwv Deferred Tax Assets Tax Deferred Expense Equity Cost
DeferredTaxAssetsTaxDeferredExpenseEquityCost
0
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1273000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
116000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
0
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
1031000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
47276000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
43215000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
47096000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
43070000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
180000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
145000
CY2023Q4 snwv Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
180000
CY2022Q4 snwv Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
145000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
180000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
145000
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2023Q4 snwv Capitalized Research And Development Costs Section174
CapitalizedResearchAndDevelopmentCostsSection174
1300000
CY2023 us-gaap Unrecognized Tax Benefits Income Tax Penalties Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
0
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
0
CY2022 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Expense
UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
0
CY2023 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Expense
UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
0
CY2023 us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<div style="font-family: 'Times New Roman'; font-size: 10pt;"> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 36pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">21.</td> <td style="width: auto; vertical-align: top;"> <div style="font-weight: bold;"><span style="font-weight: bold; color: rgb(0, 0, 0);">Commitments and Contingencies</span></div> </td> </tr> </table> </div> <div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Litigation</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In the ordinary course of business, the Company from time to time becomes involved in various legal proceedings involving a variety of matters. The Company does not believe there are any pending legal proceedings that will have a material adverse effect on the Company’s business, consolidated financial position, results of operations, or cash flows. However, the outcome of such legal matters is inherently unpredictable and subject to significant uncertainties. The Companies expenses legal fees in the period in which they are occurred.</div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <div style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">In February 2024, the Company entered into a termination agreement with an advisor to agree on termination fees owed with respect to a previous engagement agreement. The company agreed to a contingent payment of $670 thousand upon the closure of the Merger disclosed in note 4.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> </div> <div style="display:none;"><br/></div> <div style="text-indent: -36pt; margin-left: 36pt; font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Acquisition Dispute</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In May 2022, the Company received notification alleging that it is not in compliance with the license agreement with Celularity entered in connection with the acquisition of the UltraMIST assets. The Company has responded and asserted that the Company is not in breach and that the supplier has breached various agreements. It is too early to determine the outcome of this matter. Any potential impact to the Company cannot be fully determined at this time.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> </div> <div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt;">Lease Commitments</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">As of December 31, 2023, the maturities of the Company’s operating and financing leases, which have initial or remaining lease terms more than one year, consist of the following:</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> <div style="color: rgb(0, 0, 0);">(In thousands)</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0);">Operating <br/> Leases</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; color: rgb(0, 0, 0);">Finance</div> <div style="text-align: center; color: rgb(0, 0, 0);">Leases</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top;" valign="bottom"> <div style="color: rgb(0, 0, 0);">Year ended December 31,</div> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: top;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom;" valign="bottom"> </td> <td colspan="2" style="vertical-align: top;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76.06%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0);">2024</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0);">141</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0);">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0);">189</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76.06%;" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0);">2025</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%;" valign="bottom"> <div style="color: rgb(0, 0, 0);">122</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%;" valign="bottom"> <div style="color: rgb(0, 0, 0);">216</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76.06%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0);">2026</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0);">67</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0);">44</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76.06%;" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0);">2027</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%;" valign="bottom"> <div style="color: rgb(0, 0, 0);">59</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%;" valign="bottom">-</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76.06%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="text-align: left; color: rgb(0, 0, 0);">2028</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> <div style="color: rgb(0, 0, 0);">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">-</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76.06%; padding-bottom: 4px;" valign="bottom"> <div style="color: rgb(0, 0, 0);">Total Lease Payments</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0);">389</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.04%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 8.99%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"> <div style="color: rgb(0, 0, 0);">449</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.04%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table>
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
141000
CY2023Q4 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
189000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
122000
CY2023Q4 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
216000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
67000
CY2023Q4 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
44000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
59000
CY2023Q4 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
0
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
0
CY2023Q4 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
0
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
389000
CY2023Q4 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
449000

Files In Submission

Name View Source Status
0001140361-24-014611-index-headers.html Edgar Link pending
0001140361-24-014611-index.html Edgar Link pending
0001140361-24-014611.txt Edgar Link pending
0001140361-24-014611-xbrl.zip Edgar Link pending
ef20015276_10k.htm Edgar Link pending
ef20015276_ex21-1.htm Edgar Link pending
ef20015276_ex23-1.htm Edgar Link pending
ef20015276_ex31-1.htm Edgar Link pending
ef20015276_ex31-2.htm Edgar Link pending
ef20015276_ex32-1.htm Edgar Link pending
ef20015276_ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ef20015276_10k_htm.xml Edgar Link completed
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snwv-20231231.xsd Edgar Link pending
snwv-20231231_def.xml Edgar Link unprocessable
snwv-20231231_lab.xml Edgar Link unprocessable
snwv-20231231_cal.xml Edgar Link unprocessable
snwv-20231231_pre.xml Edgar Link unprocessable